WO2011156641A2 - Microneedle arrays for active agent delivery - Google Patents
Microneedle arrays for active agent delivery Download PDFInfo
- Publication number
- WO2011156641A2 WO2011156641A2 PCT/US2011/039858 US2011039858W WO2011156641A2 WO 2011156641 A2 WO2011156641 A2 WO 2011156641A2 US 2011039858 W US2011039858 W US 2011039858W WO 2011156641 A2 WO2011156641 A2 WO 2011156641A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- microneedles
- base
- subject
- microneedle
- active agent
- Prior art date
Links
- 239000013543 active substance Substances 0.000 title claims abstract description 65
- 238000003491 array Methods 0.000 title abstract description 47
- 238000000034 method Methods 0.000 claims abstract description 66
- 229960005486 vaccine Drugs 0.000 claims abstract description 46
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 10
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 10
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 10
- 238000011081 inoculation Methods 0.000 claims abstract description 7
- 108020004459 Small interfering RNA Proteins 0.000 claims description 42
- 239000000463 material Substances 0.000 claims description 39
- 230000028993 immune response Effects 0.000 claims description 29
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 23
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 23
- 238000002255 vaccination Methods 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 13
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 12
- 210000000987 immune system Anatomy 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 9
- 229930091371 Fructose Natural products 0.000 claims description 6
- 239000005715 Fructose Substances 0.000 claims description 6
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 6
- 230000000007 visual effect Effects 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 230000004936 stimulating effect Effects 0.000 claims description 4
- 238000012795 verification Methods 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 3
- 229920000856 Amylose Polymers 0.000 claims description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- 229920002101 Chitin Polymers 0.000 claims description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 3
- 239000001856 Ethyl cellulose Substances 0.000 claims description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 3
- 229920001800 Shellac Polymers 0.000 claims description 3
- 229920002125 Sokalan® Polymers 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- 229920002494 Zein Polymers 0.000 claims description 3
- 235000010443 alginic acid Nutrition 0.000 claims description 3
- 229920000615 alginic acid Polymers 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 3
- 229960001631 carbomer Drugs 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- 229940105329 carboxymethylcellulose Drugs 0.000 claims description 3
- 235000010418 carrageenan Nutrition 0.000 claims description 3
- 239000000679 carrageenan Substances 0.000 claims description 3
- 229920001525 carrageenan Polymers 0.000 claims description 3
- 229940113118 carrageenan Drugs 0.000 claims description 3
- 239000008121 dextrose Substances 0.000 claims description 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 3
- 229920001249 ethyl cellulose Polymers 0.000 claims description 3
- 229960004667 ethyl cellulose Drugs 0.000 claims description 3
- 229930182830 galactose Natural products 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 150000004676 glycans Chemical class 0.000 claims description 3
- 238000010255 intramuscular injection Methods 0.000 claims description 3
- 239000007927 intramuscular injection Substances 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- 235000010981 methylcellulose Nutrition 0.000 claims description 3
- 229960002900 methylcellulose Drugs 0.000 claims description 3
- 229920001282 polysaccharide Polymers 0.000 claims description 3
- 239000005017 polysaccharide Substances 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 239000004208 shellac Substances 0.000 claims description 3
- 229940113147 shellac Drugs 0.000 claims description 3
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims description 3
- 235000013874 shellac Nutrition 0.000 claims description 3
- 235000010413 sodium alginate Nutrition 0.000 claims description 3
- 239000000661 sodium alginate Substances 0.000 claims description 3
- 229940005550 sodium alginate Drugs 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 239000005019 zein Substances 0.000 claims description 3
- 229940093612 zein Drugs 0.000 claims description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 3
- 102000014150 Interferons Human genes 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 229940079322 interferon Drugs 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 230000003444 anaesthetic effect Effects 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 74
- 241000699666 Mus <mouse, genus> Species 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 17
- 239000010408 film Substances 0.000 description 15
- 101150039392 CBL3 gene Proteins 0.000 description 13
- 101150058299 Cblc gene Proteins 0.000 description 13
- 102100035275 E3 ubiquitin-protein ligase CBL-C Human genes 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 238000003384 imaging method Methods 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 210000002615 epidermis Anatomy 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 8
- 238000000799 fluorescence microscopy Methods 0.000 description 7
- 238000011068 loading method Methods 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 210000000434 stratum corneum Anatomy 0.000 description 7
- 108060001084 Luciferase Proteins 0.000 description 6
- 239000005089 Luciferase Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 210000004207 dermis Anatomy 0.000 description 6
- 230000035515 penetration Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 5
- 238000011529 RT qPCR Methods 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 230000005284 excitation Effects 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 4
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 4
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 4
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000013613 expression plasmid Substances 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000003278 mimic effect Effects 0.000 description 4
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000037317 transdermal delivery Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- -1 vaccines Proteins 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000021375 Xenogenes Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 239000013590 bulk material Substances 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 108010021843 fluorescent protein 583 Proteins 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 108060006184 phycobiliprotein Proteins 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- 206010003497 Asphyxia Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 238000011771 FVB mouse Methods 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 241001427367 Gardena Species 0.000 description 1
- 102100040445 Keratin, type I cytoskeletal 14 Human genes 0.000 description 1
- 101710183391 Keratin, type I cytoskeletal 14 Proteins 0.000 description 1
- 101000614435 Mus musculus Keratin, type I cytoskeletal 14 Proteins 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 238000012634 optical imaging Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/20—Surgical instruments, devices or methods, e.g. tourniquets for vaccinating or cleaning the skin previous to the vaccination
- A61B17/205—Vaccinating by means of needles or other puncturing devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0023—Drug applicators using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/003—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles having a lumen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0046—Solid microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0053—Methods for producing microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0061—Methods for using microneedles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Definitions
- Transdermal delivery of various active agents has been a common and effective way for delivering active agents to subjects.
- active agents that can be difficult to deliver transdermally include nucleic acids, vaccines, proteins, microorganisms, and the like.
- a major obstacle for the delivery of these active agents is overcoming the stratum corneum barrier.
- the natural function of the stratum corneum is to prevent water loss and exclude external agents from entering the body with a molecular cut off of about -500 Da.
- the present invention provides microneedle arrays, associated systems, and methods that can be used to deliver various therapeutic agents, including nucleic acids and vaccines.
- a method of delivering a therapeutically effective amount of an active agent to a subject is provided.
- a microneedle array comprising a base portion and a plurality of microneedles attached to the base portion is provided.
- the microneedles can have a
- the microneedles are applied a skin surface of a subject in a manner sufficient to embed the microneedles into the skin surface.
- the base of the microneedle array can then be separated from the microneedles such that the microneedles remain embedded in the skin surface and the base is removed from the skin surface.
- the microneedles can be maintained in the skin surface until the microneedles are absorbed (i.e. dissolved in the skin), or otherwise removed by the subject.
- a method of providing visual verification of microneedle placement in a skin surface includes providing a microneedle array including a plurality of microneedles attached to the microneedle array, wherein at least one of the microneedles includes an indicator.
- the microneedle array is applied a skin surface of a subject such that the microneedles are embedded into the skin surface and then verifying of successful application of the microneedles can be made through observation of the indicators presence in the skin.
- a method of vaccinating includes provoking an immune response, including a localized immune response, in a subject in need of vaccination and delivering a vaccine concomitantly with the provocation of the immune response.
- a method may include providing a microneedle array comprising a base and microneedle attached to the base.
- the microneedles can be loaded with an amount of a vaccine sufficient to provide inoculation to the subject.
- the microneedle array can be applied to a skin surface of a subject such that the microneedles are embedded into the skin surface.
- the base of the microneedle array can be separated from the microneedles such that the microneedles remain embedded in the skin surface and the base is removed from the skin surface.
- the microneedles can be maintained in the skin surface until the microneedles are absorbed by the subject.
- a method of minimizing the amount of vaccine required to effectively vaccinate a subject against a disease for which the vaccine is effective includes stimulating an immune response in the subject at a vaccination site while concomitantly delivering of the vaccination.
- a microneedle device is also provided.
- the microneedle device includes a therapeutically effective amount of an active agent, a base, and a plurality of microneedles attached to the base.
- the microneedles can have at least one external longitudinal channel that contains at least a portion of the active agent.
- a microneedle device is provided that includes a therapeutically effective amount of an active agent, a base, and a plurality of microneedles attached to the base.
- the microneedles can include a lower portion and an upper portion. The lower portion can be adjacent to the base and the upper portion can be opposite the base. The lower portion and said upper portion can be compositionally distinct.
- a system for delivering siR A to a subject can include a therapeutically effective amount of a self-delivering siRNA and a microneedle array.
- the microneedle array can include a base and a plurality of microneedles attached to the base.
- the microneedles can include a bioabsorbable/biodegradable material and can be configured to be detached from the base after being embedded in a skin surface.
- FIG. 1 shows a schematic of one embodiment of a method of fabrication of a microneedle array and example images.
- C. Protrusions are subsequently trimmed to the desired length and tip shape.
- FIG. 2 shows imaging of individual microneedle penetration sites in vivo and microneedle plug visualization in skin sections.
- A Microneedle arrays were loaded with siGLO Red (a fluorescently-tagged siRNA mimic, -20 ng/microneedle) and applied to the left footpad. As a control, 0.5 ⁇ g of siGLO Red (in 50 ⁇ PBS) was injected intradermally into the right footpad. Mice were immediately intravitally imaged for fluorescence using the Xenogen IVIS 200 system. Localized fluorescence corresponding to individual microneedle penetration sites was observed following microneedle array application.
- B Fluorescence microscopy of 10 ⁇ skin sections showing a microneedle depot loaded with siGLO Red (longer exposure time [not shown] shows initial release of siGLO Red) demonstrating drug release to the epidermis.
- FIG. 3 shows fluorescence microscopy analysis of Accell Red siRNA distribution in mouse footpad skin.
- Transgenic CBL/hMGFP mouse footpads were treated with two (3x5) microneedle arrays loaded with Accell Red (DY-547-labelled) non-targeting siRNA.
- Mice were sacrificed at 1.5 (A,B) and 6 (C,D) h after microneedle array application and footpad skin sections removed for analysis.
- Accell Red siRNA red fluorescence, middle panels
- FIG. 4 shows CBL3 Accell siRNA-loaded microneedle arrays inhibit hMGFP expression in mouse footpad skin.
- Transgenic CBL/hMGFP mouse footpads were treated every two days with three (3x5) microneedle arrays loaded with either CBL3 or non-specific control Accell siRNA for 12 days.
- Total RNA, isolated from paw palm skin of three mice treated with CBL3 Accell siRNA (right footpad) or a non-specific control Accell siRNA (left footpad) was reverse transcribed and hMGFP mRNA levels quantified by qPCR. The hMGFP levels were normalized to K14 levels (endogenous control).
- FIG. 5 shows analysis of fLuc reporter gene expression in mouse ear and footpads following microneedle array-mediated delivery of expression plasmids.
- the ear on the right was treated with a microneedle array loaded with approximately 12 ng/microneedle of pGL3-CMV-Luc plasmid (12 microneedles).
- the ear on the left was treated with the delivery device loaded with PBS vehicle alone.
- Microneedle arrays were inserted into the ear for 20 min. After 24 h, luciferase expression was determined following IP luciferin injection by whole animal imaging using the Xenogen IVIS 200 in vivo system (red is the highest expression level, blue lowest).
- B. Footpad delivery Right footpads were treated with microneedle arrays (12 microneedles) loaded with luciferase expression plasmid for two consecutive days and analyzed as described above. Left footpads were treated with microneedle arrays loaded with PBS vehicle alone (control).
- FIG. 6 shows fluorescence microscopy of mouse footpad skin sections demonstrates microarray-mediated siGLO Red (fluorescently-labeled siRNA mimic) delivery to the epidermis (or dermis).
- siGLO Red fluorescently-labeled siRNA mimic
- the term "about” is used to provide flexibility to a numerical range endpoint by providing that a given value may be “a little above” or “a little below” the endpoint.
- subject refers to a mammal that may benefit from the administration using a transdermal device or method of this invention.
- subjects include humans, and other animals such as horses, pigs, cattle, dogs, cats, rabbits, and aquatic mammals.
- active agent or “drug” are used interchangeably and refer to a pharmacologically active substance or composition.
- concomitantly when used to describe the stimulation of an immune response in conjunction with the delivery of a vaccination refers to the overlap in time between the stimulation of the immune response and the vaccination.
- the actual stimulation of the immune system need not take place simultaneously with the actual administration of the vaccination. Rather, concomitant stimulation of the immune system with delivery of the vaccine merely requires that the immune system be stimulated to an elevated level shortly before, during, or shortly after administration or delivery of the vaccine.
- any combination or sequence of administration and immunostimulation which results in improved recognition by the body of the vaccine is suitably qualified as concomitant administration.
- the stimulation when stimulation occurs before vaccination, the stimulation should be within a time period that the immune system is still at an elevated level when the vaccine is delivered/administered. In some cases, when the stimulation occurs after vaccination, the stimulation should be within a time period that the immune system is stimulated to the elevated level within 24 hours of delivery of the vaccination, preferably within 12 hours of vaccination.
- self-delivery siRNA or “self-delivering siR A” can be used interchangeably and refer to R Ai compounds that are modified to enable delivery to target cells and organs and efficient cellular uptake without the use of a delivery vehicle such as a transfection reagent.
- Non-limiting examples of commercially available self-delivering siRNA compounds that can be used in the systems and methods of the present invention include rxRNATM compounds such as rxRNAonTM, rxRNAso/oTM and sd-rxRNATM by RXI
- an "external longitudinal channel” is defined as being a channel or groove that runs along at least a portion of the longitudinal axis of the microneedle and which is open to the outside or exterior of the microneedle along at least a portion of its length.
- the term “substantially” refers to the complete or nearly complete extent or degree of an action, characteristic, property, state, structure, item, or result.
- sequences, compounds, formulations, delivery mechanisms, or other items may be presented in a common list for convenience. However, these lists should be construed as though each member of the list is individually identified as a separate and unique member. Thus, no individual member of such list should be construed as a de facto equivalent of any other member of the same list solely based on their presentation in a common group without indications to the contrary.
- the present invention provides microneedle arrays, associated systems, and methods that can be used to deliver various therapeutic agents, including nucleic acids and vaccines.
- a method of delivering a therapeutically effective amount of an active agent to a subject is provided.
- a microneedle array comprising a base portion and a plurality of microneedles attached to the base portion are provided.
- the microneedles can have a therapeutically effective amount of an active agent included therein.
- the microneedles are applied to a skin surface of a subject in a manner sufficient to embed the microneedles into the skin surface.
- the base of the microneedle array can then be separated from the microneedles such that the microneedles remain embedded in the skin surface and the base is removed from the skin surface.
- the microneedles can be maintained in the skin surface until the microneedles are absorbed by the subject.
- a method of providing visual verification of microneedle placement in a skin surface includes providing a microneedle array including a plurality of microneedles attached to the microneedle array, wherein at least one of the microneedles includes an indicator.
- the microneedle array is applied a skin surface of a subject such that the microneedles are embedded into the skin surface and then verifying successful application of the microneedles can be made through observation of the indicators presence in the skin.
- a method of vaccinating includes provoking an immune response in a subject in need of vaccination and delivering a vaccine concomitantly with the provocation of the immune response.
- a method of vaccinating a subject in thereof includes providing a microneedle array comprising a base and microneedle attached to the base.
- the microneedles can be loaded with an amount of a vaccine sufficient to provide inoculation to the subject.
- the microneedle array can be applied to a skin surface of a subject such that the microneedles are embedded into the skin surface.
- the base of the microneedle array can be separated from the microneedles such that the microneedles remain embedded in the skin surface and the base is removed from the skin surface.
- the microneedles can be maintained in the skin surface until the microneedles are absorbed by the subject.
- a method of minimizing the amount of vaccine required to effectively vaccinate a subject against a disease for which the vaccine is effective is provided. The method includes stimulating an immune response in the subject at a vaccination site while concomitantly with delivery of the vaccination.
- a microneedle device is also provided.
- the microneedle device includes a
- a microneedle device that includes a therapeutically effective amount of an active agent, a base, and a plurality of microneedles attached to the base.
- the microneedles can include a lower portion and an upper portion. The lower portion can be adjacent to the base and the upper portion can be opposite the base. The lower portion and said upper portion can be compositionally distinct.
- a system for delivering siR A to a subject can include a therapeutically effective amount of a self-delivering siRNA and a microneedle array.
- the microneedle array can include a base and a plurality of microneedles attached to the base.
- the microneedles can include a bioabsorbable/biodegradable material and can be configured to be detached from the base after being embedded in a skin surface.
- the natural function of the stratum corneum is to prevent water loss and exclude external agents from entering the body with a molecular cut off of about -500 Da.
- the microneedles array of the present invention can effectively circumvent this barrier by direct skin penetration.
- the microneedles arrays of the present invention can be made of bioabsorbable/biodegradable materials and provide the added benefit that the tips may be left in the skin and can act as reservoirs, releasing the active agents over extended periods of time while the microneedles are dissolved and absorbed into the body of the subject
- the microneedle arrays of the present invention can be configured to include a base portion and a plurality of microneedles attached to the base.
- the microneedles can be substantially perpendicular to the base and can be configured to be detached from the based after they are embedded into a skin surface. Once the microneedles are embedded into the skin surface, the base can be separated from the microneedles and removed from the skin surface. By leaving the microneedles in the skin surface, the active agents present in the microneedles can continue to be delivered.
- the microneedles of the present invention can have at least one external longitudinal channel which is open along at least a portion of its length to the outside of the microneedle.
- the microneedles can have several of these longitudinal channels.
- Such longitudinal channels are distinct from enclosed tubes that can be present in the microneedles and can have openings at the tops (tip end) or bottoms (base end) but not along the length of the microneedles.
- the longitudinal channels can be loaded with the active agents delivered by the microneedle arrays.
- the longitudinal channels can act to increase the surface area of the microneedle thereby increasing the rate of release of the active agent into the subject. Further, the longitudinal channels can also act to facilitate the loading of the microneedles with the active agent or other compounds.
- the microneedles can also be configured to have a lower portion and an upper portion, the lower portion being adjacent to the base and the upper portion being opposite the base or at the tip of the microneedle.
- the lower portion and the upper portion of the microneedle can be compositionally distinct.
- the active agent can be present only in the upper portion of the microneedle.
- the active agent can be present only in the lower portion of the microneedle.
- the microneedle can include two different active agents, a first active agent being present in the lower portion and a second active agent being present in the upper portion.
- the microneedles of the microneedle arrays of the present invention can be made of bioabsorbable/biodegradable materials.
- bioabsorbable/biodegradable materials include polyvinyl alcohol, polyvinylpyrrolidone, and other polymers, chitin, carboxymethyl cellulose, methyl cellulose, ethyl cellulose, sodium alginate, carrageenan, carbomer, alginates, and other polysaccharides, shellac, zein and other proteins, glucose, sucrose, maltose, trehalose, amylose, dextrose, fructose, mannose, galactose, fructose, and other sugars, mixtures thereof, and copolymers thereof, generally only limited by the ability to create a viscous solution in a solvent that can volatilize during formation of the fiber-like needle structure.
- the bioabsorbable/biodegradable material is polyvinyl alcohol.
- the weight average molecular weight (MW) of the polyvinyl alcohol can be over 10,000 amu.
- the base of the microneedle arrays of the present invention can be made of any material known in the art onto which the microneedles can be attached and subsequently separated. In one embodiment, the base of the microneedle array can be made of the same
- the base can be flexible to facilitate application to curved skin surfaces.
- the active agents that can be delivered using the microneedle arrays and associated methods are wide ranging.
- the active agent can be a vaccine.
- the vaccine may be in the form of a micro-organism, either attenuated or non-attenuated, toxoids, protein subunits, and or conjugates.
- the active agent can be a nucleic acid.
- nucleic acids that can be delivered include modified and unmodified DNA or RNA including siRNA and plasmids.
- the active agent delivered by the microneedles of the microneedle array is a self-delivering siRNA.
- the microneedles of the microneedle arrays can include a second active agent selected from the group consisting of an immune system stimulator, a local anesthetic, a systemic drug, a hormone, and/or combinations thereof.
- the immune system stimulator can be an interferon.
- the microneedles of the microneedle arrays can also include an indicator capable of providing visual verification of microneedle placement in the skin surface.
- the indicator can be incorporated into the body of the microneedle, loaded onto the exterior of the microneedle, or loaded into the microneedle along with the drug, or any combination thereof.
- the indicator can, but need not be present in all of the microneedles of the microneedle array. Further, the indicator can be present in the microneedles of the microneedle array so as to form an image when the microneedles are embedded in the skin.
- the image of the microneedle array can be specific to the particular active agent delivered by the microneedle array, thereby allowing a practitioner to know not only if the microneedles had been properly embedded into the skin of the subject, but also what type of active agent was received by the subject. This can be particularly advantageous when the subject may be in need of receiving multiple active agents, such as multiple vaccines.
- the image can be that of a creative or fun nature for the enjoyment and purposes of children or others receiving vaccination as such visual indicators will remain as a "tattoo" on the skin until the microneedles dissolve or are absorbed.
- the indicator can be a dye.
- the dye can be deposited onto the exterior of at least one of the microneedles on the microneedle array using an ink-jet apparatus, by contacting the needles with a surface upon which the dye is previously deposited in a pattern, or by contacting dye with needle structures individually in an indexed fashion.
- the indicator can be one that is only visible upon direct application of a light source. In one aspect, the indicator can be visible only after application ultra-violet and/or infrared light.
- the indicator can also be a biological indicator.
- the indicator can be a fluorophore such as fluoresceine.
- the indicator can be a bioluminescent enzyme such as a luciferase.
- the needles may be loaded with an active agent such as those described above either by including this agent in the bulk material from which the needle structures are formed, by adding material to the surface of the film from which the needles are pulled, or by loading the needles after they are fully formed, or by a combination of these methods.
- an active agent such as those described above either by including this agent in the bulk material from which the needle structures are formed, by adding material to the surface of the film from which the needles are pulled, or by loading the needles after they are fully formed, or by a combination of these methods.
- an active agent payload such as a fluorescein model drug may be co-dissolved with the polymer or dry component(s) of the film, or it may be dissolved (or suspended if poorly soluble) in this viscous solution prior to dispensing as a film from which needle structures will be pulled.
- An active agent included in this manner will be distributed throughout the needle structures and the backing material in rough proportion to the quantity of material in each part.
- the resulting needles pulled from this surface-loaded PVA film are strongly colored by the fluorescein payload, while the backing material remains relatively pale in coloration, indicating that the majority of the fluorescein is incorporated into the needles.
- a second, thinner PVA film containing a drug can be applied in the same manner, or a film containing material to be incorporated besides PVA, with similar preferential incorporation into the needle structures.
- the needles are brought into brief contact with a solution containing active agent dissolved or suspended in a volatile phase, and subsequently this phase is evaporated, depositing the active payload as a component of the needle structure.
- the volatile phase will also swell or dissolve the material of which the needle is formed, for example a water solution in contact with a PVA needle
- the needle can additionally imbibe the solvent material, and can carry payload material into the matrix of structural material that forms the needle.
- a 1% fluorescein solution in water will efficiently wet the surface of a dry PVA needle structure, being drawn into superficial channels along the needle length.
- a method of vaccinating can include provoking an immune response in a subject in need of vaccination and delivering a vaccine concomitantly with the provocation of the immune response. It is noted that the provoking of the immune response is intended to refer to an immune response that is in addition to the immune response that would be associated with the delivery of the vaccine. In some aspects, the immune response may be a localized response, at or around, the site of the microneedle administration.
- the vaccine By provoking the immune response, the vaccine can have an increased effectiveness in achieving the desired inoculation.
- the provocation of the immune response can be accomplished, at least in part, by leaving the microneedles in the skin until they are absorbed by the subject's body.
- the microneedles persistence in the skin tissue may stimulate an increased immune response, including but not limited to in the skin, thereby enhancing the ability of the immune system to recognize the presence of the vaccine, and thus elevate the immune response to a higher level than the vaccine alone.
- This enhanced immune response can function to increase the effectiveness of the vaccine.
- the presence of the microneedles enhances the immune response such that the effective amount of vaccine sufficient to provide inoculation to the subject is less than the amount of vaccine needed when delivered via intramuscular injection.
- a method of minimizing the amount of vaccine required to effectively vaccinate a subject against a disease for which the vaccine is effective is provided. The method includes stimulating an immune response in the subject at a vaccination site concomitantly with delivery of the vaccination. Because of the body's increased ability to recognize the vaccine due to the immune response concomitantly sparked, less vaccine is required than would otherwise be required with other vaccination methods, for example, intramuscular injection.
- Microneedle arrays were produced by bringing a pin template into contact with a 1 mm thick film of 20% wt. polyvinyl alcohol (PVA) solution (FIG. 1A, left and middle panels), and withdrawing the template under a controlled air flow to produce fiber-like structures with loadable channels (FIG. 1 A, right panel and B).
- PVA polyvinyl alcohol
- the dried needle structures are separated from the template, and mechanically trimmed to a uniform height with sharp beveled tips (FIG. 1C).
- Typical fabrication and drying of microneedle arrays occurs at or below 50°C (as low as 30°C, data not shown), below established siR A degradation temperatures.
- the device is removed from the substrate as a regular array of dissolvable microneedles with an integral material backing (FIG. ID).
- the microneedles on the microneedle arrays can be less than 100 ⁇ thick, with a sharp tip only microns across (FIG. IE).
- Microneedle arrays can be loaded with aqueous solutions or suspensions of payload materials, such as nucleic acids, drugs, vaccines, or other therapeutic agents. Multiple payloads can be delivered from separate needle populations on the same array (FIG. IF). To show the flexibility of loading, phycobiliprotein R- phycoerythrin and fluorescein were alternatively loaded on arrays, demonstrating that multiple cargos can be delivered with a single device (FIG. IF).
- Microneedle arrays were produced using an assembly of commercially available "pin headers" (Header Strip 80 pin dual row 1 mm spacing, PED-80S-P2, PAN PACIFIC, Santa Cruz, CA), as templates.
- the fabrication of the microneedles was accomplished by bringing the template pattern of projections into contact with a 1 mm thick film of 20% wt. polyvinyl alcohol (SPECTRUM, Gardena, CA) polymer solution on a glass substrate (Microscope Slides #1324L Globe Scientific, Paramus, NJ). Following contact with the polymer film, the projections were withdrawn a distance of 1 cm over 13 s under a uniform airflow of 3.0 m s at 45°C.
- SPECTRUM polyvinyl alcohol
- needle structures can be formed in the film with a hollow interior or exterior groove, which can be subsequently loaded through "capillary action.”
- Such microneedles were produced and mechanically trimmed to a nominal 1.0 mm length and 45 degree bevel, and loaded with "cargos” including nucleic acids (siRNAs and plasmids, see below), proteins (phycobiliprotein R-phycoerythrin) or dyes (e.g. fluorescein ).
- the microneedle arrays were incubated in a 50°C vacuum oven evacuated to -18 cm mercury pressure for four hours to "harden” microneedles to facilitate skin penetration (the thin backing layer remains flexible, allowing conformation to skin contours during application).
- Microneedle arrays were applied manually to subjects such that the needle tips pierced the outermost skin surface by giving to the back of the array a single flick with the finger and were left in place for 20 minutes. During this period, the needle tips hydrated below the skin surface and softened to form a viscous gel plug. After this hydration period, the dry outer portion was removed, leaving the hydrated portions, with their cargo, embedded in the application site.
- Microneedle arrays were loaded with -20 ng/microneedle of the DY-547 (a Cy3 analog 557 nm excitation, 570 nm emission) fluorescently-tagged siRNA mimic siGLO Red or Accell Red Non-Targeting siRNA (Dharmacon Products, Thermo Fisher Scientific, Lafayette, CO).
- the microneedle arrays were applied to the left paw of an FVB mouse using four consecutive applications of arrays (1x4) containing four microneedles each. Each microneedle array was applied for 20 minutes to maximize hydration of the penetrating microneedles.
- the right paw received 0.5 ⁇ g of siGLO Red in 50 ⁇ PBS solution via intradermal injection.
- Mouse paws were imaged in an IVIS 200 imaging system using the DsRed filter set (excitation at 460-490 nm and 500-550 nm; emissions at 575-650 nm) during 1 s acquisition time.
- the resulting emitted light was quantified using Livinglmage software (Caliper
- Microneedle arrays in 3x5 array format were also applied to FVB or Tg hMGFP/CBL mice. Following C0 2 asphyxiation at the indicated times, skin tissue was dissected and frozen sections analyzed using a red filter set (546 nm excitation; 580 nm emission) in an Axio Observer Inverted Fluorescence Microscope (Zeiss, Thornwood, NY) to visualize release from microneedle and biodistribution of siRNAs in skin. The images were taken with an AxioCam MRm (Zeiss) camera using AxioVs40 V4.6.3.0 software (Zeiss).
- Microneedle arrays were loaded with a fluorescently -tagged siRNA mimic (siGLO Red) and applied to the left paw footpad.
- siGLO Red fluorescently -tagged siRNA mimic
- PBS solution was injected intradermally into the right paw.
- Localized fluorescence corresponding to individual microneedle penetration sites could be visualized in vivo (FIG. 2A).
- the signal detected in the left paw was equal to the signal detected following intradermal injection of 0.5 ⁇ g into the right paw (data not shown).
- Individual microneedles loaded with siGLO Red could be observed penetrating the stratum corneum barrier to form localized depots in both the epidermis (FIG. 2B, and FIG. 6) and dermis (FIG. 6).
- mice were treated and the effect on reporter gene expression was analyzed.
- Three microneedle arrays (3x5 microneedle arrays) were applied to paw skin every other day for 12 days. On day 13' the mice were sacrificed, palm skin excised and CBL/hMGFP reporter mRNA levels were measured by RT-qPCR (FIG. 4A).
- a significant reduction (up to 50%) in expression was found in all three CBL3 siRNA-treated palms compared to the counterpart palms treated with non-specific control siRNA. No significant reduction was found in footpads treated with non-specific siRNAs and footpads treated with empty microneedle arrays (data not shown), although variability was observed between individuals.
- Microneedle arrays containing approximately -20 ng/microneedle of Accell CBL3 and non-specific control Accell siRNAs (Dharmacon) were applied for 20 minutes to right and left footpads, respectively, of Tg CBL/hMGFP mice anesthetized with 2% isofluorane. Mice were treated every 48 h with three arrays (4x5) per treatment for 12 days. The mice were sacrificed on day 13 of the experiment and treated footpad tissues removed. Footpad skin from one mouse per cohort was embedded in O.C.T. compound (Tissue-Tek®, Torrance, CA) and frozen in dry ice.
- O.C.T. compound Tissue-Tek®, Torrance, CA
- mice were sacrificed and skin tissues removed, pad and palm regions separated from the footpad, and frozen directly in dry ice. Tissue was
- Microneedle arrays containing firefly luciferase (fLuc) expression plasmid were applied to mouse back, ear and paw skin. Following luciferin administration 24 h later, luciferase expression was assayed by in vivo bioluminescence imaging (BLI). Luminescence was detected in all the treated skin types (left ear and footpad are shown in FIG. 5A and B, respectively; data not shown for back skin expression) while no expression was found in skin treated with microneedle arrays loaded with PBS vehicle alone.
- Example 8 In vivo delivery of plasmid DNA using Microneedle Arrays
- Microneedle arrays (3x4) were loaded with approximately 12 ng/microneedle of pGL3-
- mice CMV-Luc plasmid and applied back, ear and footpad skin of anesthetized (2% isofluorane) mice for 20 minutes. 24 and 48 h following the array application, the mice were IP injected with luciferin (100 ⁇ of 30 mg/ml luciferin; 150 mg/kg body weight) and the live anesthetized mice imaged 10 min later in the IVIS 200 Imaging System as previously described. The resulting light emission was quantified using Livinglmage software as described above.
Abstract
The present invention provides for microneedle arrays and related systems and methods. Particularly, microneedle arrays that are configured to deliver active agents, including nucleic acids and vaccines, are provided. Additional related methods of vaccinating and minimizing the amount of vaccine necessary for effective inoculation are also provided.
Description
MICRONEEDLE ARRAYS FOR ACTIVE AGENT DELIVERY
PRIORITY DATA
This application claims the benefit of U.S. Provisional Patent Application Serial No. 61/353,108, filed on June 9, 2010, which is incorporated herein by reference.
BACKGROUND
Transdermal delivery of various active agents has been a common and effective way for delivering active agents to subjects. Unfortunately, there are significant challenges associated with the delivery of some types of active agents due to their complexity and size. Examples of active agents that can be difficult to deliver transdermally include nucleic acids, vaccines, proteins, microorganisms, and the like. A major obstacle for the delivery of these active agents is overcoming the stratum corneum barrier. The natural function of the stratum corneum is to prevent water loss and exclude external agents from entering the body with a molecular cut off of about -500 Da. With this in mind, research continues into methods for providing effective transdermal delivery of these types of active agents.
SUMMARY OF THE INVENTION
The present invention provides microneedle arrays, associated systems, and methods that can be used to deliver various therapeutic agents, including nucleic acids and vaccines. In one embodiment, a method of delivering a therapeutically effective amount of an active agent to a subject is provided. A microneedle array comprising a base portion and a plurality of microneedles attached to the base portion is provided. The microneedles can have a
therapeutically effective amount of an active agent included therein. The microneedles are applied a skin surface of a subject in a manner sufficient to embed the microneedles into the skin surface. The base of the microneedle array can then be separated from the microneedles such that the microneedles remain embedded in the skin surface and the base is removed from the skin surface. The microneedles can be maintained in the skin surface until the microneedles are absorbed (i.e. dissolved in the skin), or otherwise removed by the subject.
In another embodiment, a method of providing visual verification of microneedle placement in a skin surface is provided. The method includes providing a microneedle array
including a plurality of microneedles attached to the microneedle array, wherein at least one of the microneedles includes an indicator. The microneedle array is applied a skin surface of a subject such that the microneedles are embedded into the skin surface and then verifying of successful application of the microneedles can be made through observation of the indicators presence in the skin.
In another embodiment, a method of vaccinating is provided. The method includes provoking an immune response, including a localized immune response, in a subject in need of vaccination and delivering a vaccine concomitantly with the provocation of the immune response. In yet another embodiment, such a method may include providing a microneedle array comprising a base and microneedle attached to the base. The microneedles can be loaded with an amount of a vaccine sufficient to provide inoculation to the subject. The microneedle array can be applied to a skin surface of a subject such that the microneedles are embedded into the skin surface. After application, the base of the microneedle array can be separated from the microneedles such that the microneedles remain embedded in the skin surface and the base is removed from the skin surface. The microneedles can be maintained in the skin surface until the microneedles are absorbed by the subject.
In an additional embodiment, a method of minimizing the amount of vaccine required to effectively vaccinate a subject against a disease for which the vaccine is effective is provided. The method includes stimulating an immune response in the subject at a vaccination site while concomitantly delivering of the vaccination.
A microneedle device is also provided. In one aspect, the microneedle device includes a therapeutically effective amount of an active agent, a base, and a plurality of microneedles attached to the base. The microneedles can have at least one external longitudinal channel that contains at least a portion of the active agent. In another embodiment, a microneedle device is provided that includes a therapeutically effective amount of an active agent, a base, and a plurality of microneedles attached to the base. The microneedles can include a lower portion and an upper portion. The lower portion can be adjacent to the base and the upper portion can be opposite the base. The lower portion and said upper portion can be compositionally distinct.
In another embodiment, a system for delivering siR A to a subject is provided. The system can include a therapeutically effective amount of a self-delivering siRNA and a microneedle array. The microneedle array can include a base and a plurality of microneedles
attached to the base. The microneedles can include a bioabsorbable/biodegradable material and can be configured to be detached from the base after being embedded in a skin surface.
BRIEF DESCRIPTION OF THE DRAWINGS
Additional features and advantages of the invention will be apparent from the detailed description which follows, taken in conjunction with the accompanying drawings, which together illustrate, by way of example, features of the invention; and, wherein:
FIG. 1 shows a schematic of one embodiment of a method of fabrication of a microneedle array and example images. A. Pin template (top, left panel) and glass slide (bottom, left panel) are covered with a thin film of viscous (20%) polyvinyl alcohol (PVA) solution (blue). The pin template is placed in contact with the PVA solution (middle panel). Microneedles are produced by withdrawing the pins as the film is drying, forming fiber-like structures (Right panel). B. Enlarged view of fibers. C. Protrusions are subsequently trimmed to the desired length and tip shape. D. Microneedle array supported by a glass substrate, with a penny to show scale. E. Micrograph of one microneedle after trimming to 1 mm length, showing beveled structure that facilitates skin penetration, with a human hair (-100 μπι diameter) to show scale. H. Microneedle arrays loaded alternatively with fluorescein (green) or R-phycoerythrin (red).
FIG. 2 shows imaging of individual microneedle penetration sites in vivo and microneedle plug visualization in skin sections. A. Microneedle arrays were loaded with siGLO Red (a fluorescently-tagged siRNA mimic, -20 ng/microneedle) and applied to the left footpad. As a control, 0.5 μg of siGLO Red (in 50 μΐ PBS) was injected intradermally into the right footpad. Mice were immediately intravitally imaged for fluorescence using the Xenogen IVIS 200 system. Localized fluorescence corresponding to individual microneedle penetration sites was observed following microneedle array application. B. Fluorescence microscopy of 10 μπι skin sections showing a microneedle depot loaded with siGLO Red (longer exposure time [not shown] shows initial release of siGLO Red) demonstrating drug release to the epidermis.
Sections were stained with DAPI to visualize nuclei (bar = 10 μπι).
FIG. 3 shows fluorescence microscopy analysis of Accell Red siRNA distribution in mouse footpad skin. Transgenic CBL/hMGFP mouse footpads were treated with two (3x5) microneedle arrays loaded with Accell Red (DY-547-labelled) non-targeting siRNA. Mice were
sacrificed at 1.5 (A,B) and 6 (C,D) h after microneedle array application and footpad skin sections removed for analysis. Accell Red siRNA (red fluorescence, middle panels) distributes through dermis (d) and epidermis (ep). With this needle design and length, the red fluorescence signal is detected in the basal (b) and spinosum (s) layers at 1.5 h (A,B) and reaches the granular layer (g) and stratum corneum (sc) at 6 h. Sections were stained with DAPI to visualize nuclei (right panel). Brightfield fluorescence overlay (left panel). Bar= 20 μπι.
FIG. 4 shows CBL3 Accell siRNA-loaded microneedle arrays inhibit hMGFP expression in mouse footpad skin. Transgenic CBL/hMGFP mouse footpads were treated every two days with three (3x5) microneedle arrays loaded with either CBL3 or non-specific control Accell siRNA for 12 days. A. RT-qPCR analysis of Tg CBL/hMGFP mice treated with CBL3 Accell siRNA. Total RNA, isolated from paw palm skin of three mice treated with CBL3 Accell siRNA (right footpad) or a non-specific control Accell siRNA (left footpad), was reverse transcribed and hMGFP mRNA levels quantified by qPCR. The hMGFP levels were normalized to K14 levels (endogenous control). Each bar corresponds to the mean of three replicates. Bars indicate standard error. B. Fluorescence microscopy of frozen skin sections prepared from treated mice. Mice were sacrificed and frozen skin sections (10 μπι) prepared. hMGFP expression (or lack thereof) was visualized by fluorescence microscopy of samples from mouse footpads treated with non-specific Accell siRNA (left panel) or CBL3 (right panel) Accell siRNA. Upper panel shows brightfield overlay and bottom panel shows fluorescence only. Scale bar is 50 μπι.
Nuclei are visualized by DAPI stain (blue). C. In vivo quantification of hMGFP fluorescence. Three mice were treated with CBL3 Accell siRNA (right paw) and non-specific Accell siRNA (left paw) and imaged with the CRi Maestro imaging system during treatment. Quantification of the region of interest adjusted to the palm of each mouse was performed using Maestro quantification software after background subtraction. The ratio in the average signal
(counts/s/mm ) of CBL3 Accell treated palm and non-specific Accell treated palm normalized to day 0 is reported in the graph. D. hMGFP expression in mouse 3 imaged during treatment with the CRi Maestro imaging system. The right paw was treated with CBL3 Accell siRNA while the left paw was treated with non-specific control Accell siRNA. Images were taken using auto- expose settings and un-mixed using previously defined spectra and autofluorescence. The images are pseudocolored green.
FIG. 5 shows analysis of fLuc reporter gene expression in mouse ear and footpads following microneedle array-mediated delivery of expression plasmids. A. Ear delivery. The ear on the right was treated with a microneedle array loaded with approximately 12 ng/microneedle of pGL3-CMV-Luc plasmid (12 microneedles). The ear on the left was treated with the delivery device loaded with PBS vehicle alone. Microneedle arrays were inserted into the ear for 20 min. After 24 h, luciferase expression was determined following IP luciferin injection by whole animal imaging using the Xenogen IVIS 200 in vivo system (red is the highest expression level, blue lowest). B. Footpad delivery. Right footpads were treated with microneedle arrays (12 microneedles) loaded with luciferase expression plasmid for two consecutive days and analyzed as described above. Left footpads were treated with microneedle arrays loaded with PBS vehicle alone (control).
FIG. 6 shows fluorescence microscopy of mouse footpad skin sections demonstrates microarray-mediated siGLO Red (fluorescently-labeled siRNA mimic) delivery to the epidermis (or dermis). When needles were detected in the epidermis, fluorescent signal was found laterally dispersed from the delivery site (A, B; -90 min timepoint) and progressively decreased through lower epidermal layers and dermis (bar = 20 μπι;). In other occasions (C, D), diffusion was detected in both the dermis and epidermis (bar = 10 μπι). When needles were detected in the dermis the fluorescent signal was rapidly dispersed (E, F; this image was taken 30 min after application, bar = 50 μπι). Sections were stained with DAPI to visualize nuclei.
Reference will now be made to the exemplary embodiments illustrated, and specific language will be used herein to describe the same. It will nevertheless be understood that no limitation of the scope of the invention is thereby intended.
DETAILED DESCRIPTION OF EXAMPLE EMBODIMENT(S)
Before particular embodiments of the present invention are disclosed and described, it is to be understood that this invention is not limited to the particular process and materials disclosed herein as such may vary to some degree. It is also to be understood that the terminology used herein is used for the purpose of describing particular embodiments only and is not intended to be limiting.
In describing and claiming the present invention, the following terminology will be used.
The singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a microneedle" includes reference to one or more microneedles, and reference to "the polymer" includes reference to one or more materials.
As used herein, the term "about" is used to provide flexibility to a numerical range endpoint by providing that a given value may be "a little above" or "a little below" the endpoint.
The term "subject" refers to a mammal that may benefit from the administration using a transdermal device or method of this invention. Examples of subjects include humans, and other animals such as horses, pigs, cattle, dogs, cats, rabbits, and aquatic mammals.
As used herein, the term "active agent" or "drug" are used interchangeably and refer to a pharmacologically active substance or composition.
As used herein, the term "concomitantly" when used to describe the stimulation of an immune response in conjunction with the delivery of a vaccination refers to the overlap in time between the stimulation of the immune response and the vaccination. The actual stimulation of the immune system need not take place simultaneously with the actual administration of the vaccination. Rather, concomitant stimulation of the immune system with delivery of the vaccine merely requires that the immune system be stimulated to an elevated level shortly before, during, or shortly after administration or delivery of the vaccine. In short, any combination or sequence of administration and immunostimulation which results in improved recognition by the body of the vaccine is suitably qualified as concomitant administration. Generally speaking, when stimulation occurs before vaccination, the stimulation should be within a time period that the immune system is still at an elevated level when the vaccine is delivered/administered. In some cases, when the stimulation occurs after vaccination, the stimulation should be within a time period that the immune system is stimulated to the elevated level within 24 hours of delivery of the vaccination, preferably within 12 hours of vaccination.
As used herein, "self-delivery siRNA" or "self-delivering siR A" can be used interchangeably and refer to R Ai compounds that are modified to enable delivery to target cells and organs and efficient cellular uptake without the use of a delivery vehicle such as a transfection reagent. Non-limiting examples of commercially available self-delivering siRNA compounds that can be used in the systems and methods of the present invention include rxRNA™ compounds such as rxRNAon™, rxRNAso/o™ and sd-rxRNA™ by RXI
Pharmaceuticals Corporation and Accell® siRNA by Thermo Scientific Dharmacon®.
As used herein, an "external longitudinal channel" is defined as being a channel or groove that runs along at least a portion of the longitudinal axis of the microneedle and which is open to the outside or exterior of the microneedle along at least a portion of its length.
As used herein, the term "substantially" refers to the complete or nearly complete extent or degree of an action, characteristic, property, state, structure, item, or result.
As used herein, sequences, compounds, formulations, delivery mechanisms, or other items may be presented in a common list for convenience. However, these lists should be construed as though each member of the list is individually identified as a separate and unique member. Thus, no individual member of such list should be construed as a de facto equivalent of any other member of the same list solely based on their presentation in a common group without indications to the contrary.
Concentrations, amounts, and other numerical data may be expressed or presented herein in a range format. It is to be understood that such a range format is used merely for convenience and brevity and thus should be interpreted flexibly to include not only the numerical values explicitly recited as the limits of the range, but also to include all the individual numerical values or sub-ranges encompassed within that range as if each numerical value and sub-range is explicitly recited. As an illustration, a numerical range of "about 0.5 to 10 g" should be interpreted to include not only the explicitly recited values of about 0.5 g to about 10.0 g, but also include individual values and sub-ranges within the indicated range. Thus, included in this numerical range are individual values such as 2, 5, and 7, and sub-ranges such as from 2 to 8, 4 to 6, etc. This same principle applies to ranges reciting only one numerical value. Furthermore, such an interpretation should apply regardless of the breadth of the range or the characteristics being described.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs. Although any methods, devices and materials similar or equivalent to those described herein can be used in the practice or testing of the invention, representative methods, devices, and materials are described below.
It is noted that when discussing the devices, systems and associated methods, each of these discussions can be considered applicable to each of these embodiments, whether or not they are explicitly discussed in the context of that embodiment. Thus, for example, in discussing
a biodegradable polymer that can be used in the methods of vaccinating, such a polymer can also be used for a microneedle array, and vice versa.
Accordingly, the present invention provides microneedle arrays, associated systems, and methods that can be used to deliver various therapeutic agents, including nucleic acids and vaccines. In one embodiment, a method of delivering a therapeutically effective amount of an active agent to a subject is provided. A microneedle array comprising a base portion and a plurality of microneedles attached to the base portion are provided. The microneedles can have a therapeutically effective amount of an active agent included therein. The microneedles are applied to a skin surface of a subject in a manner sufficient to embed the microneedles into the skin surface. The base of the microneedle array can then be separated from the microneedles such that the microneedles remain embedded in the skin surface and the base is removed from the skin surface. The microneedles can be maintained in the skin surface until the microneedles are absorbed by the subject.
In another embodiment, a method of providing visual verification of microneedle placement in a skin surface is provided. The method includes providing a microneedle array including a plurality of microneedles attached to the microneedle array, wherein at least one of the microneedles includes an indicator. The microneedle array is applied a skin surface of a subject such that the microneedles are embedded into the skin surface and then verifying successful application of the microneedles can be made through observation of the indicators presence in the skin.
In another embodiment, a method of vaccinating is provided. The method includes provoking an immune response in a subject in need of vaccination and delivering a vaccine concomitantly with the provocation of the immune response. In yet another embodiment, a method of vaccinating a subject in thereof is provided. The method includes providing a microneedle array comprising a base and microneedle attached to the base. The microneedles can be loaded with an amount of a vaccine sufficient to provide inoculation to the subject. The microneedle array can be applied to a skin surface of a subject such that the microneedles are embedded into the skin surface. After application, the base of the microneedle array can be separated from the microneedles such that the microneedles remain embedded in the skin surface and the base is removed from the skin surface. The microneedles can be maintained in the skin surface until the microneedles are absorbed by the subject.
In an additional embodiment, a method of minimizing the amount of vaccine required to effectively vaccinate a subject against a disease for which the vaccine is effective is provided. The method includes stimulating an immune response in the subject at a vaccination site while concomitantly with delivery of the vaccination.
A microneedle device is also provided. The microneedle device includes a
therapeutically effective amount of an active agent, a base, and a plurality of microneedles attached to the base. The microneedles can have at least one external longitudinal channel that contains at least a portion of the active agent. In another embodiment, a microneedle device is provided that includes a therapeutically effective amount of an active agent, a base, and a plurality of microneedles attached to the base. The microneedles can include a lower portion and an upper portion. The lower portion can be adjacent to the base and the upper portion can be opposite the base. The lower portion and said upper portion can be compositionally distinct.
In another embodiment, a system for delivering siR A to a subject is provided. The system can include a therapeutically effective amount of a self-delivering siRNA and a microneedle array. The microneedle array can include a base and a plurality of microneedles attached to the base. The microneedles can include a bioabsorbable/biodegradable material and can be configured to be detached from the base after being embedded in a skin surface.
A major obstacle to transdermal delivery of certain active agents, including siRNAs and vaccines, is the challenge of getting the active agents through the stratum corneum barrier. The natural function of the stratum corneum is to prevent water loss and exclude external agents from entering the body with a molecular cut off of about -500 Da. The microneedles array of the present invention can effectively circumvent this barrier by direct skin penetration. Further, the microneedles arrays of the present invention can be made of bioabsorbable/biodegradable materials and provide the added benefit that the tips may be left in the skin and can act as reservoirs, releasing the active agents over extended periods of time while the microneedles are dissolved and absorbed into the body of the subject
The microneedle arrays of the present invention can be configured to include a base portion and a plurality of microneedles attached to the base. The microneedles can be substantially perpendicular to the base and can be configured to be detached from the based after they are embedded into a skin surface. Once the microneedles are embedded into the skin surface, the base can be separated from the microneedles and removed from the skin surface. By
leaving the microneedles in the skin surface, the active agents present in the microneedles can continue to be delivered.
The microneedles of the present invention can have at least one external longitudinal channel which is open along at least a portion of its length to the outside of the microneedle. In some embodiments, the microneedles can have several of these longitudinal channels. Such longitudinal channels are distinct from enclosed tubes that can be present in the microneedles and can have openings at the tops (tip end) or bottoms (base end) but not along the length of the microneedles. The longitudinal channels can be loaded with the active agents delivered by the microneedle arrays. The longitudinal channels can act to increase the surface area of the microneedle thereby increasing the rate of release of the active agent into the subject. Further, the longitudinal channels can also act to facilitate the loading of the microneedles with the active agent or other compounds.
The microneedles can also be configured to have a lower portion and an upper portion, the lower portion being adjacent to the base and the upper portion being opposite the base or at the tip of the microneedle. In one embodiment, the lower portion and the upper portion of the microneedle can be compositionally distinct. In one embodiment, the active agent can be present only in the upper portion of the microneedle. In another embodiment, the active agent can be present only in the lower portion of the microneedle. In yet a further embodiment, the microneedle can include two different active agents, a first active agent being present in the lower portion and a second active agent being present in the upper portion.
The microneedles of the microneedle arrays of the present invention can be made of bioabsorbable/biodegradable materials. Non-limiting examples of bioabsorbable/biodegradable materials that can be used include polyvinyl alcohol, polyvinylpyrrolidone, and other polymers, chitin, carboxymethyl cellulose, methyl cellulose, ethyl cellulose, sodium alginate, carrageenan, carbomer, alginates, and other polysaccharides, shellac, zein and other proteins, glucose, sucrose, maltose, trehalose, amylose, dextrose, fructose, mannose, galactose, fructose, and other sugars, mixtures thereof, and copolymers thereof, generally only limited by the ability to create a viscous solution in a solvent that can volatilize during formation of the fiber-like needle structure. In the present invention, polymeric or glassy materials that are water-soluble are preferred due to their ability to hydrate in skin and be biologically cleared through absorption. In one embodiment, the bioabsorbable/biodegradable material is polyvinyl alcohol. When the
bioabsorbable/biodegradable polymer is polyvinyl alcohol, the weight average molecular weight (MW) of the polyvinyl alcohol can be over 10,000 amu.
The base of the microneedle arrays of the present invention can be made of any material known in the art onto which the microneedles can be attached and subsequently separated. In one embodiment, the base of the microneedle array can be made of the same
bioabsorbable/biodegradable material as the microneedles. Typically, the base can be flexible to facilitate application to curved skin surfaces.
The active agents that can be delivered using the microneedle arrays and associated methods are wide ranging. In one embodiment, the active agent can be a vaccine. The vaccine may be in the form of a micro-organism, either attenuated or non-attenuated, toxoids, protein subunits, and or conjugates. In embodiment, the active agent can be a nucleic acid. Non- limiting examples of nucleic acids that can be delivered include modified and unmodified DNA or RNA including siRNA and plasmids. In one embodiment, the active agent delivered by the microneedles of the microneedle array is a self-delivering siRNA.
In addition to the above listed active agents, additional active agents may be co-delivered with these active agents. In one embodiment, the microneedles of the microneedle arrays can include a second active agent selected from the group consisting of an immune system stimulator, a local anesthetic, a systemic drug, a hormone, and/or combinations thereof. In one embodiment, the immune system stimulator can be an interferon.
The microneedles of the microneedle arrays can also include an indicator capable of providing visual verification of microneedle placement in the skin surface. The indicator can be incorporated into the body of the microneedle, loaded onto the exterior of the microneedle, or loaded into the microneedle along with the drug, or any combination thereof. The indicator can, but need not be present in all of the microneedles of the microneedle array. Further, the indicator can be present in the microneedles of the microneedle array so as to form an image when the microneedles are embedded in the skin. In one embodiment, the image of the microneedle array can be specific to the particular active agent delivered by the microneedle array, thereby allowing a practitioner to know not only if the microneedles had been properly embedded into the skin of the subject, but also what type of active agent was received by the subject. This can be particularly advantageous when the subject may be in need of receiving multiple active agents, such as multiple vaccines. Furthermore, the image can be that of a creative or fun nature
for the enjoyment and purposes of children or others receiving vaccination as such visual indicators will remain as a "tattoo" on the skin until the microneedles dissolve or are absorbed.
Generally, any biologically acceptable indicator known in the art can be used. In one embodiment, the indicator can be a dye. In one aspect, the dye can be deposited onto the exterior of at least one of the microneedles on the microneedle array using an ink-jet apparatus, by contacting the needles with a surface upon which the dye is previously deposited in a pattern, or by contacting dye with needle structures individually in an indexed fashion. In another embodiment, the indicator can be one that is only visible upon direct application of a light source. In one aspect, the indicator can be visible only after application ultra-violet and/or infrared light. The indicator can also be a biological indicator. In one embodiment, the indicator can be a fluorophore such as fluoresceine. In another embodiment, the indicator can be a bioluminescent enzyme such as a luciferase.
Generally, the needles may be loaded with an active agent such as those described above either by including this agent in the bulk material from which the needle structures are formed, by adding material to the surface of the film from which the needles are pulled, or by loading the needles after they are fully formed, or by a combination of these methods.
In the case in which the bulk material is loaded, an active agent payload, such as a fluorescein model drug may be co-dissolved with the polymer or dry component(s) of the film, or it may be dissolved (or suspended if poorly soluble) in this viscous solution prior to dispensing as a film from which needle structures will be pulled. An active agent included in this manner will be distributed throughout the needle structures and the backing material in rough proportion to the quantity of material in each part.
In the case in which payload material is added to the surface of the film, without wishing to be bound to a particular interpretation, it is observed that material on the surface of the film from which needle structures are formed is preferentially drawn into the needle structures pulled from this film, and needles thus formed are subsequently found to be enriched in any material that was thus surface-loaded relative to the quantity of that material in an equivalent volume of the backing material. Thus surface-loading of the film provides an enhancement of the efficiency of use of an active agent. For example, an ethanolic solution of 1 % wt fluorescein model drug can be applied to the surface of a PVA film at a loading of about 20 uL per square cm, prior to needle formation. The resulting needles pulled from this surface-loaded PVA film
are strongly colored by the fluorescein payload, while the backing material remains relatively pale in coloration, indicating that the majority of the fluorescein is incorporated into the needles. Similarly a second, thinner PVA film containing a drug can be applied in the same manner, or a film containing material to be incorporated besides PVA, with similar preferential incorporation into the needle structures.
In the case in which payload material is loaded into/onto the needle structures after these structures are fully formed, the needles are brought into brief contact with a solution containing active agent dissolved or suspended in a volatile phase, and subsequently this phase is evaporated, depositing the active payload as a component of the needle structure. In the case that the volatile phase will also swell or dissolve the material of which the needle is formed, for example a water solution in contact with a PVA needle, it is understood that the needle can additionally imbibe the solvent material, and can carry payload material into the matrix of structural material that forms the needle. For example, a 1% fluorescein solution in water will efficiently wet the surface of a dry PVA needle structure, being drawn into superficial channels along the needle length. Because PVA is hydrated and solubilized by water, a needle thus exposed becomes flexible and pliant, indicating that the water has diffused into the bulk PVA material comprising the needle structure. Coloration of a needle thus treated indicates that the fluorescein payload material also penetrates into the needle structure. Additionally, though such loading contact time is brief, typically less than one second, it is understood that some dissolution and re-deposition of the PVA needle material must take place, which may further incorporate payload into the bulk of the needle structure.
As discussed above, the present invention also provides for methods of vaccinating a subject as well as a method for minimizing the amount of vaccine required to effectively vaccinate a subject against a disease for which the vaccine is effective is provided. In one embodiment, a method of vaccinating can include provoking an immune response in a subject in need of vaccination and delivering a vaccine concomitantly with the provocation of the immune response. It is noted that the provoking of the immune response is intended to refer to an immune response that is in addition to the immune response that would be associated with the delivery of the vaccine. In some aspects, the immune response may be a localized response, at or around, the site of the microneedle administration. By provoking the immune response, the vaccine can have an increased effectiveness in achieving the desired inoculation. In one aspect
of the invention, the provocation of the immune response can be accomplished, at least in part, by leaving the microneedles in the skin until they are absorbed by the subject's body. Without being limited by theory, it is believed that the microneedles persistence in the skin tissue may stimulate an increased immune response, including but not limited to in the skin, thereby enhancing the ability of the immune system to recognize the presence of the vaccine, and thus elevate the immune response to a higher level than the vaccine alone. This enhanced immune response can function to increase the effectiveness of the vaccine. In particular, in one embodiment of the invention, the presence of the microneedles enhances the immune response such that the effective amount of vaccine sufficient to provide inoculation to the subject is less than the amount of vaccine needed when delivered via intramuscular injection. Accordingly, in another embodiment, a method of minimizing the amount of vaccine required to effectively vaccinate a subject against a disease for which the vaccine is effective is provided. The method includes stimulating an immune response in the subject at a vaccination site concomitantly with delivery of the vaccination. Because of the body's increased ability to recognize the vaccine due to the immune response concomitantly sparked, less vaccine is required than would otherwise be required with other vaccination methods, for example, intramuscular injection.
EXAMPLES Example 1 - Microneedle Array Device Preparation
Microneedle arrays were produced by bringing a pin template into contact with a 1 mm thick film of 20% wt. polyvinyl alcohol (PVA) solution (FIG. 1A, left and middle panels), and withdrawing the template under a controlled air flow to produce fiber-like structures with loadable channels (FIG. 1 A, right panel and B). The dried needle structures are separated from the template, and mechanically trimmed to a uniform height with sharp beveled tips (FIG. 1C). Typical fabrication and drying of microneedle arrays occurs at or below 50°C (as low as 30°C, data not shown), below established siR A degradation temperatures. The device is removed from the substrate as a regular array of dissolvable microneedles with an integral material backing (FIG. ID). Typically, the microneedles on the microneedle arrays can be less than 100 μπι thick, with a sharp tip only microns across (FIG. IE). Microneedle arrays can be loaded with aqueous solutions or suspensions of payload materials, such as nucleic acids, drugs, vaccines, or
other therapeutic agents. Multiple payloads can be delivered from separate needle populations on the same array (FIG. IF). To show the flexibility of loading, phycobiliprotein R- phycoerythrin and fluorescein were alternatively loaded on arrays, demonstrating that multiple cargos can be delivered with a single device (FIG. IF).
Example 2 - Microneedle Array Device Preparation, Delivery and Application
Microneedle arrays were produced using an assembly of commercially available "pin headers" (Header Strip 80 pin dual row 1 mm spacing, PED-80S-P2, PAN PACIFIC, Santa Cruz, CA), as templates. The fabrication of the microneedles was accomplished by bringing the template pattern of projections into contact with a 1 mm thick film of 20% wt. polyvinyl alcohol (SPECTRUM, Gardena, CA) polymer solution on a glass substrate (Microscope Slides #1324L Globe Scientific, Paramus, NJ). Following contact with the polymer film, the projections were withdrawn a distance of 1 cm over 13 s under a uniform airflow of 3.0 m s at 45°C. Under these conditions, needle structures can be formed in the film with a hollow interior or exterior groove, which can be subsequently loaded through "capillary action." Such microneedles were produced and mechanically trimmed to a nominal 1.0 mm length and 45 degree bevel, and loaded with "cargos" including nucleic acids (siRNAs and plasmids, see below), proteins (phycobiliprotein R-phycoerythrin) or dyes (e.g. fluorescein ). Subsequent to loading, the microneedle arrays were incubated in a 50°C vacuum oven evacuated to -18 cm mercury pressure for four hours to "harden" microneedles to facilitate skin penetration (the thin backing layer remains flexible, allowing conformation to skin contours during application). Microneedle arrays were applied manually to subjects such that the needle tips pierced the outermost skin surface by giving to the back of the array a single flick with the finger and were left in place for 20 minutes. During this period, the needle tips hydrated below the skin surface and softened to form a viscous gel plug. After this hydration period, the dry outer portion was removed, leaving the hydrated portions, with their cargo, embedded in the application site.
Example 3 - Analysis of siRNA Distribution in Mouse Footpad Skin
Microneedle arrays were loaded with -20 ng/microneedle of the DY-547 (a Cy3 analog 557 nm excitation, 570 nm emission) fluorescently-tagged siRNA mimic siGLO Red or Accell Red Non-Targeting siRNA (Dharmacon Products, Thermo Fisher Scientific, Lafayette, CO).
The microneedle arrays were applied to the left paw of an FVB mouse using four consecutive applications of arrays (1x4) containing four microneedles each. Each microneedle array was applied for 20 minutes to maximize hydration of the penetrating microneedles. As a positive control, the right paw received 0.5 μg of siGLO Red in 50 μΐ PBS solution via intradermal injection. Mouse paws were imaged in an IVIS 200 imaging system using the DsRed filter set (excitation at 460-490 nm and 500-550 nm; emissions at 575-650 nm) during 1 s acquisition time. The resulting emitted light was quantified using Livinglmage software (Caliper
LifeSciences), written as an overlay on Igor image analysis software (WaveMetrics, Inc; Lake Oswego, Oregon). DsRed background was subtracted and raw values were reported as photons per second per cm per steradian. Microneedle arrays in 3x5 array format were also applied to FVB or Tg hMGFP/CBL mice. Following C02 asphyxiation at the indicated times, skin tissue was dissected and frozen sections analyzed using a red filter set (546 nm excitation; 580 nm emission) in an Axio Observer Inverted Fluorescence Microscope (Zeiss, Thornwood, NY) to visualize release from microneedle and biodistribution of siRNAs in skin. The images were taken with an AxioCam MRm (Zeiss) camera using AxioVs40 V4.6.3.0 software (Zeiss).
Example 4 - Microneedle Array Delivery of siRNA Across the Stratum Corneum
Microneedle arrays were loaded with a fluorescently -tagged siRNA mimic (siGLO Red) and applied to the left paw footpad. As a control, siGLO Red in PBS solution was injected intradermally into the right paw. Localized fluorescence corresponding to individual microneedle penetration sites could be visualized in vivo (FIG. 2A). After four applications of arrays (each containing four microneedles corresponding to a total deliverable dose of approximately 160-320 ng), the signal detected in the left paw was equal to the signal detected following intradermal injection of 0.5 μg into the right paw (data not shown). Individual microneedles loaded with siGLO Red could be observed penetrating the stratum corneum barrier to form localized depots in both the epidermis (FIG. 2B, and FIG. 6) and dermis (FIG. 6).
Example 5 - Silencing of CBL/hMGFP Reporter Gene in Transgenic Mouse Epidermis
In order to test the ability of microneedle arrays to deliver functional CBL3 siRNA, mouse footpads were treated and the effect on reporter gene expression was analyzed. Three microneedle arrays (3x5 microneedle arrays) were applied to paw skin every other day for 12
days. On day 13' the mice were sacrificed, palm skin excised and CBL/hMGFP reporter mRNA levels were measured by RT-qPCR (FIG. 4A). A significant reduction (up to 50%) in expression was found in all three CBL3 siRNA-treated palms compared to the counterpart palms treated with non-specific control siRNA. No significant reduction was found in footpads treated with non-specific siRNAs and footpads treated with empty microneedle arrays (data not shown), although variability was observed between individuals. In addition to mRNA reduction, decreased signal from reporter protein was also observed by fluorescence microscopy of footpad sections (FIG. 4B) of skin treated with CBL3 Accell siRNA (right panel) but not control siRNA (left panel). The reduced reporter mRNA levels on each mouse analyzed correlated well with the amount of protein reduction measured by in vivo fluorescence imaging (FIG. 4C). Representative images (mouse 3) demonstrating inhibition are shown in FIG. 4D.
Example 6 - In vivo Delivery of siRNAs Using Microneedle Arrays and Analysis of Gene Silencing
Microneedle arrays containing approximately -20 ng/microneedle of Accell CBL3 and non-specific control Accell siRNAs (Dharmacon) were applied for 20 minutes to right and left footpads, respectively, of Tg CBL/hMGFP mice anesthetized with 2% isofluorane. Mice were treated every 48 h with three arrays (4x5) per treatment for 12 days. The mice were sacrificed on day 13 of the experiment and treated footpad tissues removed. Footpad skin from one mouse per cohort was embedded in O.C.T. compound (Tissue-Tek®, Torrance, CA) and frozen in dry ice. Vertical cross sections (10 μπι) were prepared and mounted with Hydromount™ (National Diagnostic, Highland Park, NJ) containing 1 μg/ml DAPI (Sigma) for nuclear staining. Tissue sections were imaged with a GFP filter set (470 nm excitation, 525 nm emission) in an Axio Observer Inverted Fluorescence Microscope equipped with an AxioCam MRm camera to visualize transgene fluorescence as described above. Prior to the initial treatment, isoflurane- anesthetized (2%) mice were intravitally-imaged using the Maestro Optical imaging system (CRi Inc., Woburn, MA, USA) as previously described and again at days 8 and 12 of the treatment regimen. Images were taken with an excitation filter of 445—490 nm and a long-pass emission filter (515 nm). Images were automatically captured at 10 nm windows from 500 to 700 nm using the Maestro software (exposure times were automatically calculated). Spectral un-mixing of the resulting cube image was performed using a user-defined hMGFP protocol. Each
spectrum was set manually by un-mixing autofluorescence from a negative non-hMGFP expressing mouse analyzed in parallel with a Tg CBL/hMGFP positive mouse. Standardized conditions and subject positioning for image acquisition facilitated meaningful comparison of data collected on different days. Regions of interest were drawn in the palm of each paw and the average signal (counts/s/mm2) was calculated. The ratio of average signal in right (CBL3) versus left (non-specific control) paws was calculated for each mouse and normalized with respect to the pretreatment analysis data. The un-mixed signal was pseudo-colored green (FIG. 4D).
For RT-qPCR analysis, three mice were sacrificed and skin tissues removed, pad and palm regions separated from the footpad, and frozen directly in dry ice. Tissue was
homogenized in a "bead beater" instrument (FastPrep®-24, FP24, from MP Biomedicals, Solon, OH) and R A isolated as previously described. R A was reverse transcribed using the
Superscript III First Strand Synthesis system (Invitrogen) and qPCR was run in the ABI 7500 Fast Sequence Detection system (Applied Biosystems, Foster City, CA) using standard procedures. hMGFP and mouse keratin 14 (Catalog #Mm00516876) Taqman® Gene Expression Assays were used as previously described. All data points reported are the mean of 3 replicate assays and error is reported as the standard error.
Example 7 - Delivery of Luciferase Expression Plasmid to Mouse Skin and Visualization of Expressed Reporter Protein by Intravital Imaging
Microneedle arrays containing firefly luciferase (fLuc) expression plasmid were applied to mouse back, ear and paw skin. Following luciferin administration 24 h later, luciferase expression was assayed by in vivo bioluminescence imaging (BLI). Luminescence was detected in all the treated skin types (left ear and footpad are shown in FIG. 5A and B, respectively; data not shown for back skin expression) while no expression was found in skin treated with microneedle arrays loaded with PBS vehicle alone. To test the consistency of plasmid delivery and expression in mouse paw skin, 12 microneedles (each containing a deliverable pay load of approximately 12 ng per microneedle of pGL3-CMV-Luc) were applied per mouse paw on day 1 and again on day 2, and imaged on day 3 by in vivo bioluminescent imaging (FIG. 5B). We observed consistent reduction in luciferase expression using this method (FIG. 5B and data not
shown; experiment was repeated five times with similar results), demonstrating that the microneedle arrays are able to reliably deliver functionally active plasmid DNA to skin cells.
Example 8 - In vivo delivery of plasmid DNA using Microneedle Arrays
Microneedle arrays (3x4) were loaded with approximately 12 ng/microneedle of pGL3-
CMV-Luc plasmid and applied back, ear and footpad skin of anesthetized (2% isofluorane) mice for 20 minutes. 24 and 48 h following the array application, the mice were IP injected with luciferin (100 μΐ of 30 mg/ml luciferin; 150 mg/kg body weight) and the live anesthetized mice imaged 10 min later in the IVIS 200 Imaging System as previously described. The resulting light emission was quantified using Livinglmage software as described above.
While the forgoing examples are illustrative of the principles of the present invention in one or more particular applications, it will be apparent to those of ordinary skill in the art that numerous modifications in form, usage and details of implementation can be made without the exercise of inventive faculty, and without departing from the principles and concepts of the invention. Accordingly, it is not intended that the invention be limited, except as by the claims set forth below.
Claims
1. A method of delivering a therapeutically effective amount of an active agent to a subject, comprising:
providing a microneedle array having a base portion and a plurality of microneedles attached to the base portion, said microneedles having a therapeutically effective amount of an active agent included therein,
applying the microneedle array to a skin surface of a subject such that the microneedles are embedded into the skin surface,
separating the base of the microneedle array from the microneedles such that the microneedles remain embedded in the skin surface and the base is removed from the skin surface, and
maintaining the microneedles in the skin surface until the microneedles are absorbed by the subject.
2. The method of claim 1 , wherein the microneedles comprise a
bioabsorbable/biodegradable material.
3. The method of claim 2, wherein the bioabsorbable/biodegradable material is selected from the group consisting of polyvinyl alcohol, polyvinylpyrrolidone, chitin,
carboxymethyl cellulose, methyl cellulose, ethyl cellulose, sodium alginate, carrageenan, carbomer, alginates, and other polysaccharides, shellac, zein, glucose, sucrose, maltose, trehalose, amylose, dextrose, fructose, mannose, galactose, fructose, and mixtures thereof.
4. The method of claim 2, wherein the bioabsorbable/biodegradable material includes
polyvinyl alcohol.
5. The method of claim 1 , wherein the microneedles include an indicator which allows provides a visual marker that shows the microneedles embedded in the skin.
6. The method of claim 5, wherein the indicator is a dye.
7. The method of claim 5, wherein the indicator forms an image on the skin of the subject.
8. The method of claim 5, wherein the indicator is visible when light is shown onto the microneedles.
9. The method of claim 5, wherein the indicator is a fluorophore.
10. The method of claim 9, wherein the flourophore includes fluorescein.
11. The method of claiml , wherein the active agent is a nucleic acid.
12. The method of claim 1 1 , wherein the nucleic acid is a self-delivering siR A.
13. The method of claim 1 , wherein the active agent is a vaccine.
14. The method of claim 1, wherein the microneedles have longitudinal channels that are configured to retain the active agent.
15. A method of providing visual verification of microneedle placement in a skin surface, comprising,
providing a microneedle array having a plurality of microneedles attached thereto, said microneedles including an indicator
applying the microneedle array to a skin surface of a subject such that the microneedles are embedded into the skin surface,
verifying successful application of the microneedles through observation of the indicator's presence in the skin.
16. The method of claim 15, wherein the indicator is a dye.
17. The method of claim 15, wherein the indicator forms an image on the skin of the subject.
18. The method of claim 15, wherein the indicator is visible when light is shown onto the microneedles.
19. The method of claim 15, wherein the indicator is a fluorophore.
20. The method of claim 19, wherein the flourophore includes fluorescein.
21. A microneedle device, comprising
an effective amount of an active agent,
a base, and
a plurality of microneedles attached to the base, said microneedles having at least one external longitudinal channel that contains at least a portion of the active agent.
22. A microneedle device, comprising
a effective amount of an active agent,
a base, and
a plurality of microneedles attached to the base, wherein the microneedles include a lower portion and an upper portion, wherein the lower portion is adjacent to the base and the upper portion is opposite the base, said lower portion and said upper portion being
compositionally distinct.
23. The system of claim 22, wherein the active agent is only present in the upper portion of the microneedles.
24. The system of claim 22, wherein the active agent is only present in the lower portion of the microneedles.
25. The system of claim 22, wherein a first active agent is present in the upper portion of the microneedles and a second active agent is present in the lower portion of the microneedles.
26. A system for delivering siRNA to a subject, comprising:
an amount of a self-delivering siRNA
a microneedle array, said microneedle array comprising
a base, and
a plurality of microneedles attached to the base, said microneedles comprising a bioabsorbable/biodegradable material and being and configured to be detached from the base after being embedded in a skin surface.
27. The system of claim 26, wherein the microneedles include a plurality of longitudinal channels.
28. The system of claim 27, wherein the self-delivering siRNA are present in the longitudinal channels.
29. The system of claim 26, wherein the bioabsorbable/biodegradable material is selected from the group consisting of polyvinyl alcohol, polyvinylpyrrolidone, chitin,
carboxymethyl cellulose, methyl cellulose, ethyl cellulose, sodium alginate, carrageenan, carbomer, alginates, and other polysaccharides, shellac, zein, glucose, sucrose, maltose, trehalose, amylose, dextrose, fructose, mannose, galactose, fructose, and mixtures thereof.
30. The system of claim 26, wherein the bioabsorbable/biodegradable material includes
polyvinyl alcohol.
31. The system of claim 26, wherein the microneedles include a lower portion and an upper portion, wherein the lower portion is adjacent to the base and the upper portion is opposite the base.
32. The system of claim 31 , wherein the upper portion of the microneedle is compositionally distinct from the lower portion of the microneedle.
33. The system of claim 31, wherein the active agent is only present in the upper portion of the microneedle.
34. The system of claim 31, wherein the active agent is only present in the lower portion of the microneedle.
35. The system of claim 26, wherein at least some of the microneedles of the microneedle array include a second active agent.
36. The system of claim 35, wherein the second active agent is selected from the group consisting of: an immune system stimulator, anesthetic, a systemic drug, a hormone, and combinations thereof.
37. The system of claim 36, wherein the immune system stimulator is an interferon.
38. A method of vaccinating a subject in need thereof, comprising:
providing a microneedle array comprising a base and microneedles attached to the base, said microneedles being loaded with an amount of a vaccine sufficient to provide inoculation to the subject,
applying the microneedle array to a skin surface of a subject such that the microneedles are embedded into the skin surface,
separating the base of the microneedle array from the microneedles such that the microneedles remain embedded in the skin surface and the base is removed from the skin surface, and maintaining the microneedles in the skin surface until the microneedles are absorbed by the subject.
39. The method of claim 38, wherein the maintaining of the microneedles in the skin surface causes an enhanced immune response.
40. The method of claim 39, wherein the enhanced immune response increases the effectiveness of the vaccination.
41. The method of claim 38, wherein the amount of vaccine sufficient to provide inoculation to the subject is less than the amount of vaccine needed when delivered via intramuscular injection.
42. A method of vaccinating, comprising:
provoking an immune response in a subject in need of a vaccination,
delivering a vaccine to the subject concomitantly with the provocation of the immune response.
43. A method of minimizing an amount of vaccine required to effectively vaccinate a subject against a disease for which the vaccine is effective, comprising: stimulating an immune response in the subject at a vaccination site concomitantly with delivery of a vaccine.
44. The method of claim 43, wherein the delivery of the vaccine is accomplished through the embedding and leaving of microneedles into a skin surface of a subject and the leaving of the microneedles in the skin provokes the immune response.
45. The method of claim 44, wherein the vaccine is delivered by the microneedles that are left in the skin.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35310810P | 2010-06-09 | 2010-06-09 | |
US61/353,108 | 2010-06-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011156641A2 true WO2011156641A2 (en) | 2011-12-15 |
WO2011156641A3 WO2011156641A3 (en) | 2012-05-10 |
Family
ID=45098675
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2011/039858 WO2011156641A2 (en) | 2010-06-09 | 2011-06-09 | Microneedle arrays for active agent delivery |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2011156641A2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180056053A1 (en) * | 2016-08-26 | 2018-03-01 | Juvic Inc. | Protruding microstructure for transdermal delivery |
WO2019018301A1 (en) * | 2017-07-16 | 2019-01-24 | Massachusetts Institute Of Technology | Microneedle tattoo patches and use thereof |
CN110680908A (en) * | 2018-07-04 | 2020-01-14 | 辽宁成大生物股份有限公司 | Rapidly disintegrating type A group C meningococcal polysaccharide conjugate vaccine soluble microneedle and preparation method thereof |
US10736840B2 (en) | 2013-09-03 | 2020-08-11 | Georgia Tech Research Corporation | Thermally stable vaccine formulations and microneedles |
WO2023081148A1 (en) * | 2021-11-03 | 2023-05-11 | Merck Sharp & Dohme Llc | Microneedle injector and methods of making and using same |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050065463A1 (en) * | 2003-09-18 | 2005-03-24 | Nano Device And System Research Inc. | Applicator for applying functional substances into human skin |
US20060127465A1 (en) * | 2003-06-10 | 2006-06-15 | Shinya Maenosono | Pad base for transdermal administration and needle |
US20070060867A1 (en) * | 2005-05-18 | 2007-03-15 | Bai Xu | High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances |
US20090043279A1 (en) * | 2007-08-06 | 2009-02-12 | Kaspar Roger L | Microneedle arrays formed from polymer films |
-
2011
- 2011-06-09 WO PCT/US2011/039858 patent/WO2011156641A2/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060127465A1 (en) * | 2003-06-10 | 2006-06-15 | Shinya Maenosono | Pad base for transdermal administration and needle |
US20050065463A1 (en) * | 2003-09-18 | 2005-03-24 | Nano Device And System Research Inc. | Applicator for applying functional substances into human skin |
US20070060867A1 (en) * | 2005-05-18 | 2007-03-15 | Bai Xu | High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances |
US20090043279A1 (en) * | 2007-08-06 | 2009-02-12 | Kaspar Roger L | Microneedle arrays formed from polymer films |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10736840B2 (en) | 2013-09-03 | 2020-08-11 | Georgia Tech Research Corporation | Thermally stable vaccine formulations and microneedles |
US20180056053A1 (en) * | 2016-08-26 | 2018-03-01 | Juvic Inc. | Protruding microstructure for transdermal delivery |
WO2019018301A1 (en) * | 2017-07-16 | 2019-01-24 | Massachusetts Institute Of Technology | Microneedle tattoo patches and use thereof |
CN111093629A (en) * | 2017-07-16 | 2020-05-01 | 麻省理工学院 | Microneedle tattoo patch and use thereof |
CN110680908A (en) * | 2018-07-04 | 2020-01-14 | 辽宁成大生物股份有限公司 | Rapidly disintegrating type A group C meningococcal polysaccharide conjugate vaccine soluble microneedle and preparation method thereof |
CN110680908B (en) * | 2018-07-04 | 2024-02-20 | 辽宁成大生物股份有限公司 | Soluble microneedle of rapidly disintegrating type A group and C group meningococcal polysaccharide conjugate vaccine and preparation method thereof |
WO2023081148A1 (en) * | 2021-11-03 | 2023-05-11 | Merck Sharp & Dohme Llc | Microneedle injector and methods of making and using same |
Also Published As
Publication number | Publication date |
---|---|
WO2011156641A3 (en) | 2012-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20180001070A1 (en) | Microneedle arrays for active agent delivery | |
Chen et al. | Dry-coated microprojection array patches for targeted delivery of immunotherapeutics to the skin | |
Wang et al. | Recent advances in the design of polymeric microneedles for transdermal drug delivery and biosensing | |
US20210213265A1 (en) | Drug-holding microneedle array and manufacturing method thereof | |
Chen et al. | Enhancing immunogenicity of antigens through sustained intradermal delivery using chitosan microneedles with a patch-dissolvable design | |
Pearton et al. | Microneedle delivery of plasmid DNA to living human skin: Formulation coating, skin insertion and gene expression | |
AU2013219321B2 (en) | Microneedle of short-time dissolution type | |
TWI554289B (en) | Embeddable patch for transdermal drug delivery and method of manufacturing the same | |
Li et al. | Individually coated microneedles for co-delivery of multiple compounds with different properties | |
DeMuth et al. | Polymer multilayer tattooing for enhanced DNA vaccination | |
WO2011156641A2 (en) | Microneedle arrays for active agent delivery | |
US10792857B2 (en) | Polymeric microneedles and rapid additive manufacturing of the same | |
US20130310665A1 (en) | Method | |
US20170112760A1 (en) | Cell delivery system and method | |
Uppu et al. | Temporal release of a three-component protein subunit vaccine from polymer multilayers | |
JP2010535591A (en) | Microneedle array formed from polymer film | |
Barnum et al. | 3D‐printed hydrogel‐filled microneedle arrays | |
US11744889B2 (en) | Skin microenvironment targeted delivery for promoting immune and other responses | |
US10869832B2 (en) | Substance delivery device and substance delivery method using the same | |
EP1956894B1 (en) | Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent | |
EP2665464A2 (en) | A carrier for oromucosal, especially sublingual administration of physiologically active substances | |
US20200330738A1 (en) | GENE SILENCING IN SKIN USING SELF-DELIVERY siRNA DELIVERED BY A MESO DEVICE | |
US20150150788A1 (en) | Method and composition for delivering a compound through a biological barrier | |
WO2018047800A1 (en) | Double-needle type microneedle | |
US20220354998A1 (en) | Hydrogel-filled microneedle arrays and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11793191 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 15/02/2013) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11793191 Country of ref document: EP Kind code of ref document: A2 |